Elaine Abrams

Last updated
Elaine Abrams
Born
Brooklyn, New York
NationalityAmerican
Alma mater Princeton University
Columbia University
Scientific career
Fields Epidemiology
InstitutionsColumbia University
Harlem Hospital Center

Elaine Abrams is an American physician and epidemiologist who is a professor of epidemiology at Columbia University. She looks to optimize the treatment of people living with HIV and prevent illness amongst children. She is a founding member of the International Center for AIDS Care and Treatment Program (ICAP) at Columbia.

Contents

Early life and education

Abrams grew up in Brooklyn. [1] Her mother was a Holocaust survivor. [1] She was an undergraduate student at Princeton University [1] and a medical student at Columbia University. [1] She completed her specialty training at the Harlem Hospital Center. [1] She was working in New York during the outbreak of the AIDS epidemic, and established the Harlem Hospital Center Family Care Center in 1989. The Center was founded to respond to the epidemic of HIV infection in young people in New York City. [1] During this time she became a fierce advocate for women's health. [1]

Research and career

Abrams works on the prevention and treatment of HIV infection in perinatal and pediatric populations. [1] She serves as a Professor of Epidemiology at Columbia University. She has designed and studied antiretroviral treatment (ART) campaigns for women pre- and post-partum, and studied the risks of vertical transmission. Her research identified environmental and biomedical factors that influence ART efficacy. [2]

Abrmas chaired the World Health Organization consolidation guidelines for the use of ART, including guidelines for dolutegravir/lamivudine/tenofovir. [3] In this capacity she was responsible for transforming access to HIV treatment. [4]

Abrams is a founding member of the Columbia University International Center for AIDS Care and Treatment Program (ICAP). With ICAP, Abrams has looked to scale-up HIV services across developing countries, including improving the lives of children. She created various programs that look to prevent HIV infections amongst children, including Positive Voices, EID Manual and PMTCT toolkit. Her work at ICAP was supported by the President's Emergency Plan for AIDS Relief (PEPfAR), which supported her efforts to provide technical assistance to the global south. [4]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

The spread of HIV/AIDS has affected millions of people worldwide; AIDS is considered a pandemic. The World Health Organization (WHO) estimated that in 2016 there were 36.7 million people worldwide living with HIV/AIDS, with 1.8 million new HIV infections per year and 1 million deaths due to AIDS. Misconceptions about HIV and AIDS arise from several different sources, from simple ignorance and misunderstandings about scientific knowledge regarding HIV infections and the cause of AIDS to misinformation propagated by individuals and groups with ideological stances that deny a causative relationship between HIV infection and the development of AIDS. Below is a list and explanations of some common misconceptions and their rebuttals.

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.

<span class="mw-page-title-main">Elizabeth Glaser Pediatric AIDS Foundation</span> Non-profit organization in the USA

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is a nonprofit organization dedicated to preventing pediatric HIV infection and eliminating pediatric AIDS through research, advocacy, and prevention and treatment programs. Founded in 1988, the organization works in 12 countries around the world.

<span class="mw-page-title-main">Opportunistic infection</span> Infection caused by pathogens that take advantage of an opportunity not normally available

An opportunistic infection is an infection caused by pathogens that take advantage of an opportunity not normally available. These opportunities can stem from a variety of sources, such as a weakened immune system, an altered microbiome, or breached integumentary barriers. Many of these pathogens do not necessarily cause disease in a healthy host that has a non-compromised immune system, and can, in some cases, act as commensals until the balance of the immune system is disrupted. Opportunistic infections can also be attributed to pathogens which cause mild illness in healthy individuals but lead to more serious illness when given the opportunity to take advantage of an immunocompromised host.

<span class="mw-page-title-main">Epidemiology of HIV/AIDS</span> Pandemic of HIV/AIDS

The global pandemic of HIV/AIDS began in 1981, and is an ongoing worldwide public health issue. According to the World Health Organization (WHO), by 2023, HIV/AIDS had killed approximately 40.4 million people, and approximately 39 million people were infected with HIV globally. Of these, 29.8 million people (75%) are receiving antiretroviral treatment. There were about 630,000 deaths from HIV/AIDS in 2022. The 2015 Global Burden of Disease Study estimated that the global incidence of HIV infection peaked in 1997 at 3.3 million per year. Global incidence fell rapidly from 1997 to 2005, to about 2.6 million per year. Incidence of HIV has continued to fall, decreasing by 23% from 2010 to 2020, with progress dominated by decreases in Eastern Africa and Southern Africa. As of 2023, there are about 1.3 million new infections of HIV per year globally.

Following infection with HIV-1, the rate of clinical disease progression varies between individuals. Factors such as host susceptibility, genetics and immune function, health care and co-infections as well as viral genetic variability may affect the rate of progression to the point of needing to take medication in order not to develop AIDS.

Christine Joy Maggiore was an HIV-positive activist and promoter of HIV/AIDS denialism. She was the founder of Alive & Well AIDS Alternatives, an organization which disputes the link between HIV and AIDS and urges HIV-positive pregnant women to avoid anti-HIV medication. Maggiore authored and self-published the book What If Everything You Thought You Knew about AIDS Was Wrong?

<span class="mw-page-title-main">Emtricitabine/tenofovir</span> Drug combination for HIV/AIDS prophylaxis and treatment

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

The human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. It is a preventable disease. It can be managed with treatment and become a manageable chronic health condition. While there is no cure or vaccine for HIV, antiretroviral treatment can slow the course of the disease and enable people living with HIV to lead long and healthy lives. An HIV-positive person on treatment can expect to live a normal life, and die with the virus, not of it. Effective treatment for HIV-positive people involves a life-long regimen of medicine to suppress the virus, making the viral load undetectable. Without treatment it can lead to a spectrum of conditions including acquired immunodeficiency syndrome (AIDS).

<span class="mw-page-title-main">Sexually transmitted infection</span> Infection transmitted through human sexual behavior

A sexually transmitted infection (STI), also referred to as a sexually transmitted disease (STD) and the older term venereal disease (VD), is an infection that is spread by sexual activity, especially vaginal intercourse, anal sex, oral sex, or sometimes manual sex. STIs often do not initially cause symptoms, which results in a risk of transmitting them on to others. The term sexually transmitted infection is generally preferred over sexually transmitted disease or venereal disease, as it includes cases with no symptomatic disease. Symptoms and signs of STIs may include vaginal discharge, penile discharge, ulcers on or around the genitals, and pelvic pain. Some STIs can cause infertility.

HIV/AIDS is considered the deadliest epidemic in the 21st century. It is transmitted through sex, intravenous drug use and mother-to-child transmission. Zambia is experiencing a generalized HIV/AIDS epidemic, with a national HIV prevalence rate of 11.3% among adults ages 15 to 49 as of 2018. Per the 2000 Zambian census, the people affected by HIV/AIDS constituted 15% of the total population, amounting to one million, of which 60% were women. The pandemic results in increased number of orphans, with an estimated 600,000 orphans in the country. It was prevalent more in urban areas compared to rural and among all provinces, Copperbelt Province and Lusaka Province had higher occurrence.

Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.

<span class="mw-page-title-main">Lauren V. Wood</span> American allergist, immunologist

Lauren V. Wood is an American allergist, immunologist, and staff physician at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in Bethesda, Maryland, where she has served as a principal investigator. She is known for conducting studies of vaccines for cancer, Human papillomavirus (HPV), Hepatitis C, and HIV especially for use with children, teens and young adults. She holds the rank of captain in the U.S. Public Health Service (PHS).

Kimberly A. Powers is an American epidemiologist who is an associate professor of epidemiology at the UNC Gillings School of Global Public Health. She combines epidemiology, statistics and mathematical modelling to understand the transmission of infectious diseases. In 2011 her work on antiretroviral therapy for the management of human immunodeficiency virus was selected by Science as the breakthrough of the year. During the COVID-19 pandemic, Powers looked to understand the spread of SARS-CoV-2.

<span class="mw-page-title-main">Judith Aberg</span> American physician

Judith Aberg is an American physician who is the George Baehr Professor of Clinical Medicine at Mount Sinai Hospital. She was appointed Dean of System Operations for Clinical Sciences at the Icahn School of Medicine at Mount Sinai. Her research considered infectious diseases, including HIV/AIDS and COVID-19.

Carolyn Barley Britton is an African-American medical doctor known for her national health care advocacy and work in neurological complications of HIV and infectious diseases. She is a full professor at Columbia University College of Physicians and Surgeons. She was the 9th female president and the 1st neurologist president of the National Medical Association.

References

  1. 1 2 3 4 5 6 7 8 "Letter from the Focal Point for Women" (PDF). The UN Women's Newsletter. 2006.
  2. "Elaine J. Abrams, MD - CROI Conference". 2020-02-16. Retrieved 2024-11-26.
  3. "LEAP | Elaine J. Abrams, MD". longactinghiv.org. Retrieved 2024-11-26.
  4. 1 2 "Who We Are". icap.columbia.edu. Retrieved 2024-11-26.